Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral LBH589 in resistant accelerated or blast phase CML
2006-002011-27Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in chronic myeloid leukemia (CML) and chronic myelogenous leukemia (CML), sponsored by Novartis. Primary endpoint: hematologic response rate. Started Nov 2006; status: completed.
02
Drugs
panobinostat
03
Conditions
chronic myeloid leukemia (CML)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2006-002011-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002011-27.